1. Abel S, Beaumont KC, Crespi CL, Eve MD, Fox L, Hyland R, Jones BC, Muirhead GJ, Smith DA, Venn RF, Walker DK (2001) Potential role for P-glycoprotein in the non-proportional pharmacokinetics of UK-343,664 in man. Xenobiotica 31:665–676
2. Altmannsberger S, Paneitz A, Franke G, Knoke M, Sperker B, Terhaag B (2000) Chronic thyroxine induces intestinal P-glycoprotein and elimination of talinolol in healthy volunteers (abstract). Eur J Clin Pharmacol 56:A16
3. Anderle P, Niederer E, Rubas W, Hilgendorf C, Spahn-Langguth H, Wunderli-Allenspach H, Merkle HP, Langguth P (1998) P-Glycoprotein (P-gp) mediated efflux in Caco-2 cell monolayers: The influence of culturing conditions and drug exposure on P-gp expression levels. J Pharm Sci 87:757–762
4. Artursson P, Karlsson J, Ócklind G, Schipper N (1996) Studying transport processes in absorptive epithelia. In: Shaw AJ (ed.), Epithelial cell culture: A practical approach, IRL Press at Oxford University Press, Oxford, New York, Tokyo, Chapter 6
5. Bhat UG, Winter MA, Pearce HL, Beck WT (1995) A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdrl and P-glycoprotein in a human colon carcinoma cell line. Mol Pharmacol 48:682–689